HAMARI will exhibit at CPhI Worldwide 2022 at Messe Frankfurt, Germany from November 1 to 3, 2022.

HAMARI’s booth is 110G41.

Please book an appointment with us and we’ll see you there!

We are taking off for the holidays! Yay!
We will be closed from August 11 to August 16.
We’ll be back on August 17th.

HAMARI will attend CPhI North America on May 17th in Pennsylvania!

HAMARI will celebrate its 73th anniversary on Friday, December 10, 2021 and will be closed for the day.

HAMARI will be closed for Winter Vacation from December 30 to January 4.

Have you heard about the United Nations’ Sustainable Development Goals (SDGs)?

Did you know that HAMARI also supports SDGs?

HAMARI’s SDGs

Hamari will be exhibiting at CPhI Worldwide 2021 in Milan from November 9 to 11, 2021!

Despite COVID-19, we will put the extra effort to meet you at CPhI Worldwide!

We look forward to your visit at our Booth 18K48.

CPhI Worldwide Website

Hamari in Japan will observe the Japanese May Holidays on April 29 and from May 3 to 5.

“Zinc and respiratory tract infections: Perspective for COVID-19 (Review)” is an international collaborative review from Germany, Greece, Norway, Russia and USA academies, centers, colleges, hospitals, institutes and universities (Int. J. Mol. Med., 46: 17-26, 2020). In this in-depth review, the authors suggested that modulation of zinc status may be beneficial in COVID-19. The SARS-CoV-2 virus is the cause of the COVID-19 pandemic leading to lung diseases, namely pneumonia, ARDS (very severe pneumonia) and ventilator-induced injuries.

1. Zinc works on the mucus lung cells by activating the removal of the virus and also inducing barrier activation, and therefore, the virus is prevented from penetrating deeper inside the body.
2. Zinc may prevent viral replication before the viral uncoding and before the viral transcription stages.
3. Zinc may boost antiviral activities by upregulating IFNα.
4. COVID-19 induces inflammation that aggravates the disease state. Zinc limits excessive inflammatory responses thereby preventing the devastative cytokine storm.
5. Bacterial co-infection from viral pneumonia is a commonly high risk. Zinc induces inhibition of Streptococcus pneumonia growth via modulation of bacterial Mn(II) homeostasis.
6. High COVID-19 mortality and zinc deficiency share the same risk factors: ageing, immune deficiency and metabolic diseases (obesity, diabetes, atherosclerosis, etc.). The authors concluded that zinc supplementation may have beneficial effects in modulating at least some of the risk factors for high COVID-19 mortality.

Hamari Chemicals, Ltd. is the inventor and manufacturer of a zinc supplement, PepZinGI.

Disclaimer: The text and illustration were composed under fair use law as a summary of a scientific review titled, “Zinc and respiratory tract infections: Perspective for COVID-19 (Review)” published in Int. J. Mol. Med., 46: 17-26, 2020.

Hamari Chemicals, Ltd. and its co-authored Professor Soloshonok and Professor Han was granted the Symmetry 2021 Best Paper Award!

Convenient Asymmetric Synthesis of Fmoc-(S)-6,6,6-Trifluoro-Norleucine.
Symmetry 2019, 11, 578. DOI: 10.3390/sym11040578

In the research article, we reported a simple high-stereoselective and high-yield synthesis method for fluorine-containing unnatural amino acids using the alkylation reaction of Soloshonok-type chiral glycine equivalent.

By establishing an efficient general synthesis method for the title compound, which is one of the important fluorine-containing unnatural amino acids, a stable supply of this unnatural amino acid was achieved. By incorporating this amino acid into peptide synthesis, the manufacture of peptides with antitumor and antibacterial properties were successful. This advancement in synthesis is expected to contribute to the development of new drugs such as fluorine-containing peptide drugs that will dramatically improve enzyme inhibitory activity.

News Release from the Publisher

Hamari would not have the resources to contribute to science and technology by publishing research studies and disclosing new technologies and knowledge in patents without your continued business

Hamari’s List of Publications

Hamari will be closed for the winter break from December 30, 2020 until January 4th, 2021. See you next year!

Hamari Chemicals, Ltd. was invited to present at
the Dietitians Australia 2021 Conference
in July 11-13, 2021.

Functional dyspepsia and Gastro-esophageal reflux disease are two highly prevalent upper GIT disorders, which significantly impair quality of life. Chelated compounds of zinc have demonstrated efficacy for addressing the symptoms and underlying drivers of upper digestive complaints and represent a compelling support to conventional drug therapy. Attendees will understand the evidence for, indications and contraindications for these key clinically trialed nutritional compounds.

Hamari will have a 20 minutes presentation focusing on PepZinGI’s safety and efficacy.

Update: Unfortunately, Hamari not be able to present at the Dietitians Australia 2021 Conference.

Several review articles on the synthesis of typical active pharmaceutical ingredients using Hamari’s Tailor-Made Amino Acids as starting materials and synthetic intermediates were published.

Applications of fluorine-containing amino acids for drug design.
Eur. J. Med. Chem. 2020, 186, 111826.

Tailor-made amino acids and fluorinated motifs as prominent traits in modern pharmaceuticals.
Chem. Eur. J. 2020, 26, 11349-11390. [Reviews Showcase]
external link: https://doi.org/10.1002/chem.202085061

Cyclic tailor-made amino acids in the design of modern pharmaceuticals.
Eur. J. Med. Chem. 2020, 208, 112736.

We, at Hamari Chemicals, Ltd., would like to express our gratitude for having received knowledge, education and support from academia, businesses and society, by sharing our discoveries at various academic societies, and publishing research articles and patents.
Hamari’s list of publications

Hamari will be taking a rest for the summer holidays from August 10 to 14. We will be back on August 17 to serve you even better!

Our headquarter has moved to its new office on July 1,2020.

Due to this relocation, we will change the address on our documents, such as invoices, issued from July 1,2020 as follows:

(Former Address)
1-4-29, Kunijima, Higashiyodogawa-ku, Osaka, 533-0024, Japan

(New Address)
1-19-40, Nankokita, Suminoe-ku, Osaka, 559-0034, Japan

The location of our domestic sales and international department at Kitahama, Osaka remains unchanged.

Hamari got published again in ChemistryOpen! It’s really interesting.

A review on Hamari Ligands was published in ACS Omega describing our core technologies and their applications.